Marta Caporale

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Morano, Salvatore Corallo et al. · JAMA Oncology · 2019 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer

Roberto Moretto, Chiara Cremolini, Daniele Rossini et al. · The Oncologist · 2016 · 102 citations

Medicine, Oncology, Pharmacology +16

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer

Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini et al. · Cancer Discovery · 2016 · 102 citations

Medicine, Oncology, Pharmacology +17

Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile et al. · The Oncologist · 2015 · 50 citations · Full text

Medicine, Oncology, Pharmacology +13

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Filippo Pietrantonio, Rosa Berenato, Claudia Maggi et al. · Journal of Translational Medicine · 2016 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +14